AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 163 filers reported holding AERIE PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 0.72 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,570,000 | +103.9% | 103,800 | +1.2% | 0.00% | 0.0% |
| Q2 2022 | $770,000 | -20.4% | 102,600 | -3.5% | 0.00% | 0.0% |
| Q1 2022 | $967,000 | +40.6% | 106,300 | +8.5% | 0.00% | – |
| Q4 2021 | $688,000 | -38.4% | 98,000 | 0.0% | 0.00% | -100.0% |
| Q3 2021 | $1,117,000 | -28.8% | 98,000 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $1,569,000 | -3.5% | 98,000 | +7.7% | 0.00% | 0.0% |
| Q1 2021 | $1,626,000 | +34.6% | 91,000 | +1.8% | 0.00% | 0.0% |
| Q4 2020 | $1,208,000 | +16.5% | 89,400 | +1.5% | 0.00% | 0.0% |
| Q3 2020 | $1,037,000 | -20.2% | 88,100 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $1,300,000 | +13.0% | 88,100 | +3.4% | 0.00% | 0.0% |
| Q1 2020 | $1,150,000 | -43.0% | 85,200 | +2.0% | 0.00% | -50.0% |
| Q4 2019 | $2,018,000 | +28.2% | 83,500 | +2.0% | 0.00% | 0.0% |
| Q3 2019 | $1,574,000 | -33.8% | 81,900 | +1.9% | 0.00% | -33.3% |
| Q2 2019 | $2,376,000 | -32.9% | 80,400 | +7.9% | 0.00% | -25.0% |
| Q1 2019 | $3,539,000 | +36.2% | 74,500 | +3.5% | 0.00% | +33.3% |
| Q4 2018 | $2,599,000 | -31.9% | 72,000 | +16.1% | 0.00% | -25.0% |
| Q3 2018 | $3,816,000 | -4.4% | 62,000 | +4.9% | 0.00% | -20.0% |
| Q2 2018 | $3,992,000 | +36.5% | 59,100 | +9.6% | 0.01% | +25.0% |
| Q1 2018 | $2,924,000 | -7.0% | 53,900 | +2.5% | 0.00% | +33.3% |
| Q4 2017 | $3,143,000 | +28.5% | 52,600 | +4.6% | 0.00% | 0.0% |
| Q3 2017 | $2,445,000 | -0.6% | 50,300 | +7.5% | 0.00% | 0.0% |
| Q2 2017 | $2,459,000 | +15.9% | 46,800 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $2,122,000 | +29.8% | 46,800 | +8.3% | 0.00% | 0.0% |
| Q4 2016 | $1,635,000 | +0.3% | 43,200 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $1,630,000 | +142.6% | 43,200 | +13.1% | 0.00% | +200.0% |
| Q2 2016 | $672,000 | +73.2% | 38,200 | +15.4% | 0.00% | 0.0% |
| Q1 2016 | $388,000 | -40.3% | 33,100 | +24.0% | 0.00% | -50.0% |
| Q4 2015 | $650,000 | +37.1% | 26,700 | 0.0% | 0.00% | +100.0% |
| Q3 2015 | $474,000 | +20.0% | 26,700 | +19.2% | 0.00% | 0.0% |
| Q2 2015 | $395,000 | -28.4% | 22,400 | +27.3% | 0.00% | 0.0% |
| Q1 2015 | $552,000 | +7.4% | 17,600 | 0.0% | 0.00% | -50.0% |
| Q4 2014 | $514,000 | – | 17,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 805,217 | $14,212,000 | 4.99% |
| DAFNA Capital Management LLC | 156,842 | $2,768,000 | 2.34% |
| NORTHPOINTE CAPITAL LLC | 1,034,400 | $18,257,000 | 2.15% |
| HARVEY CAPITAL MANAGEMENT INC | 223,200 | $3,856,000 | 1.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,211,644 | $39,036,000 | 1.30% |
| Boulegeris Investments, Inc. | 88,660 | $1,565,000 | 1.12% |
| Partner Investment Management, L.P. | 43,623 | $770,000 | 1.08% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 150,000 | $2,648,000 | 0.92% |
| PFM Health Sciences, LP | 1,851,564 | $32,680,000 | 0.83% |
| Benchmark Capital Advisors | 55,400 | $978,000 | 0.69% |